Refine by
Patient Care Management Articles & Analysis
179 news found
The ultra-sensitive, personalized MRD assay identifies up to 1,800 somatic variants unique to a patient’s tumor supporting physicians in making informed, individualized management decisions for patients. ...
ByTempus
The iGEM (International Genetically Engineered Machine) Competition is an annual event in synthetic biology. Teams participating in iGEM typically spend several months conducting research, designing their projects, and building their biological systems. These projects can range from addressing real-world problems in areas such as healthcare, environmental sustainability, and manufacturing, to ...
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
Proprietary data and software from both platforms will be used to create novel AI-based applications to improve the entire surgical continuum, including medical billing, patient pathway management, and revenue assurance. The collaboration will leverage a secure infrastructure that is compliant with data privacy, information security, and regulatory concerns ...
CD Genomics, a global leader in genomic and bioinformatics solutions, is pleased to announce the official launch of its Viral Metagenomic Sequencing service. This state-of-the-art offering represents a major advancement in the field of pathogen research and promises to provide unparalleled insights into viral communities. Viruses, being the most abundant entities on our planet, play a pivotal ...
This study confirms the significant body of evidence that pressure measurements are not adequate substitutes for direct measurements of circulating volume and that both metrics add valuable but different clinical data for the management of patients. Our BVA test informs clinicians with precise information to help manage and treat volume ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon ...
By eliminating the need for additional immunohistochemistry, 4D Path’s cloud-based platform accelerates complete, actionable and objective insight leading to expedited and democratized precision medicine for optimized patient care and clinical trials. 4D Path’s cloud-based, quantitative approach provides clinical solutions in both companion ...
We truly believe that our continued ability to deliver leading results in healthcare delivery for Original Medicare patients across the country is validation of ApolloMed's physician-centric, tech-enabled, value-based care model. This is, at its core, a superior level of care coordination and population health management that ...
“I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to create an incredibly simple solution for patients with congestive heart failure. The Bodyport solution will reduce common monitoring ...
Having a treatment that can help patients breathe easier and live a better quality of life, without surgical intervention, will be a major step forward in COPD care in ...
Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who reported having a blood glucose meter that includes an app claimed they use the app regularly. Over half of patients surveyed agreed that they consistently follow their healthcare ...
ByLifeScan
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...
“We’re living in the age of personalized medicine, where precision algorithms can be used to optimize outcomes for patients,” said Susan Wood, PhD, president and CEO of VIDA. “The addition of deep-learning capabilities to our already-proven solution is a critical step towards diagnosing and treating lung disease with anatomical precision based on clinical ...
Michael Feldschuh, CEO and President for Daxor said, “Heart failure management is centered around effective volume management. Many patients go home feeling better but end up back in the hospital due to persistent volume overload. The Centers for Medicare and Medicaid Services (CMS) will not reimburse for patients who ...
This large data set provides further benefits for patients, providers and ultimately clinical research for the future of predictive monitoring. ...
Moving forward, we must extend the medical home with a mix of retail, virtual and at-home care. Convenient, medically accurate blood testing gives providers real-time insights to inform and adjust care plans, make medication adjustments, counsel patients on condition management, and add new interventions and treatment options. ...
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...